Resources

SGLT-2 inhibitors were associated with more acute renal failure reports than other diabetes medications.

New study suggests improvement in quality of life and obesity seen with liraglutide compared with placebo.

Sensor-augmented therapy can diminish hypoglycemia with the low-glucose suspend feature.

Living with diabetes often leads me to wonder if what I’m experiencing—particularly when it’s an irritated joint or an overuse injury—is a consequence of being a regularly physically active person, getting older, or having diabetes, or some combination of those. Which one of these is causing my joint issues? Is it possible to know? I will attempt to answer these questions based on my deeper dive into the published research.

A 62-year-old Asian-American female arrives at your office for a new patient appointment. Her current medications are metformin, pioglitazone, enalapril, lovastatin, alendronate, calcium supplements and vitamin D. Her A1C is on target at 6.9%, however you decide to replace her pioglitazone with a different antihyperglycemic medication. Why would you make this decision? A. Pioglitazone increases the risk of hypertriglyceridemia B. Pioglitazone increases the risk for cardiovascular events C. Pioglitazone increases the risk for fractures D. Pioglitazone increases the risk for hypoglycemia Follow the link to see the right answer.

Are you open to recommending an SGLT-2 inhibitor as a second drug for a patient with type 2 diabetes who is overweight and has not met their goal? Follow the link to see how you compare to your colleagues.

OptiScanner is the first-of-its-kind bedside blood monitoring platform that provides plasma-based, automated monitoring of ICU patients’ glucose levels. The OptiScanner 5000 directly measures plasma glucose levels using an integrated blood centrifuge and spectrometer to help avoid dangerous glycemic variations and assist clinicians in achieving the right level of glucose control.

Pharmacy innovator Keith Campbell, B.Pharm, MBA, CDE, who sits on our board of advisors at Diabetes in Control, is one of the first pharmacists to become a certified diabetes educator and the inspiration for hundreds of other pharmacists and nurses who since followed in his footsteps, received the Lifetime Achievement Award on Friday, Oct. 20, 2017 at the Washington State University College of Pharmacy Crimson Gala.

Sheri R. Colberg, PhD, FACSM is Professor Emerita of Exercise Science from Old Dominion University and an internationally recognized authority on diabetes and exercise. She is the author of 11 books, 24 book chapters, and over 300 articles. The author of "Exercise and Diabetes: A Clinician's Guide to Prescribing Physical Activity," published by ADA in 2013, she is also the lead author on a new ADA position statement on physical activity and diabetes published last fall. In 2016, she received the ADA Outstanding Educator in Diabetes Award.

Sheri Colberg discusses her work as a diabetes educator and author, and the challenges and benefits of exercising with diabetes.